1. Home
  2. SKYE vs IAE Comparison

SKYE vs IAE Comparison

Compare SKYE & IAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • IAE
  • Stock Information
  • Founded
  • SKYE 2012
  • IAE 2007
  • Country
  • SKYE United States
  • IAE United States
  • Employees
  • SKYE N/A
  • IAE N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • IAE Trusts Except Educational Religious and Charitable
  • Sector
  • SKYE Health Care
  • IAE Finance
  • Exchange
  • SKYE Nasdaq
  • IAE Nasdaq
  • Market Cap
  • SKYE 80.7M
  • IAE 65.2M
  • IPO Year
  • SKYE N/A
  • IAE N/A
  • Fundamental
  • Price
  • SKYE $1.81
  • IAE $6.30
  • Analyst Decision
  • SKYE Buy
  • IAE
  • Analyst Count
  • SKYE 6
  • IAE 0
  • Target Price
  • SKYE $16.60
  • IAE N/A
  • AVG Volume (30 Days)
  • SKYE 1.7M
  • IAE 46.3K
  • Earning Date
  • SKYE 05-08-2025
  • IAE 01-01-0001
  • Dividend Yield
  • SKYE N/A
  • IAE 10.21%
  • EPS Growth
  • SKYE N/A
  • IAE N/A
  • EPS
  • SKYE N/A
  • IAE N/A
  • Revenue
  • SKYE N/A
  • IAE N/A
  • Revenue This Year
  • SKYE N/A
  • IAE N/A
  • Revenue Next Year
  • SKYE N/A
  • IAE N/A
  • P/E Ratio
  • SKYE N/A
  • IAE N/A
  • Revenue Growth
  • SKYE N/A
  • IAE N/A
  • 52 Week Low
  • SKYE $1.14
  • IAE $5.31
  • 52 Week High
  • SKYE $13.49
  • IAE $6.45
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 48.48
  • IAE 61.98
  • Support Level
  • SKYE $1.36
  • IAE $6.19
  • Resistance Level
  • SKYE $2.30
  • IAE $6.33
  • Average True Range (ATR)
  • SKYE 0.21
  • IAE 0.08
  • MACD
  • SKYE 0.02
  • IAE 0.03
  • Stochastic Oscillator
  • SKYE 42.35
  • IAE 90.24

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About IAE Voya Asia Pacific High Dividend Equity Income Fund ING Asia Pacific High Dividend Equity Income Fund of Beneficial Interest

Voya Asia Pacific High Dividend Equity Income Fund is a United States-based diversified, closed-end fund.The investment objective of the fund is to provide a total return through a combination of current income, capital gains, and capital appreciation. To achieve this objective, under normal market conditions, the fund invests in a portfolio of dividend-yielding equity securities of companies located in the Asia Pacific region.

Share on Social Networks: